Wheeler Bio Enhances Platform with miFuc™ Technology Licensing
Wheeler Bio Expands Capabilities with ATUM's miFuc™ Technology
Wheeler Bio, Inc., a forward-thinking contract development and manufacturing organization (CDMO), has recently made an exciting announcement regarding the enhancement of their service offerings. The company has signed a licensing agreement with ATUM to utilize the innovative miFuc™ platform. This technology specializes in the expression of recombinant proteins that contain afucosylated glycans, significantly advancing the capabilities of Wheeler Bio's Portable CMC® platform.
What is miFuc™ Technology?
ATUM's miFuc™ technology has established itself as a leader in the industry, facilitating the development of antibodies with marked reductions in fucosylation. This innovation ensures that product titer, cellular growth rates, and global glycan liabilities remain unaffected. By incorporating ATUM's proprietary Leap-In Transposase technology, antibodies produced using miFuc™ expression vectors demonstrate significantly improved antibody-dependent cellular cytotoxicity (ADCC). This enhancement leads to greater efficacy for specific therapeutics, optimizing their performance.
Advantages of the Licensing Agreement
This strategic license agreement empowers Wheeler Bio's clients by providing them the opportunity to produce therapeutic antibodies that feature improved effector engagement and enhanced ADCC. Such advancements facilitate broader therapeutic windows while mitigating toxicity risks, thus improving patient outcomes.
Integration of Advanced Technologies
Wheeler Bio has a track record of integrating cutting-edge technologies from ATUM, including the VectorGPS design platform and miCHO™ host cell line, within their Portable CMC® process platform. This integration provides a reliable, predictable, and scalable process for rapidly transitioning antibodies from the discovery phase into clinical manufacturing. The latest licensing deal further amplifies Wheeler Bio's antibody platform capabilities, enabling the production of afucosylated antibodies and an array of recombinant proteins, thus catering to a wider range of therapeutic needs.
The Focus on Integrated CMC Development
The company is dedicated to offering comprehensive CMC development and CGMP clinical supply solutions to biotechnology firms that strive to develop antibody therapeutics. Through their open-source antibody platform, the Portable CMC®, Wheeler Bio ensures that emerging biotech companies can access premium development and manufacturing services, effectively guiding them from initial discovery to early-phase clinical trials.
Accelerating the Development Workflow
One of the impressive features of ATUM's Leap-In Transposases technology is its ability to facilitate a robust cell line development workflow. This encompasses cell line generation and engineering, yielding productive pools and clones that consistently maintain product titer and quality. Combining ATUM's advanced protein expression tools with Wheeler Bio's Portable CMC® platform enables a streamlined and efficient process, significantly enhancing the journey of discovery compounds as they transition through lead candidate selection to clinical manufacturing.
Jesse McCool, the CEO and co-founder of Wheeler Bio, expressed enthusiasm for the collaboration, stating, "We are thrilled to partner again with ATUM on another blend of ATUM and Wheeler Bio technologies. With ATUM's miFuc™ technology integrated into our Portable CMC® platform, our clients can enjoy greater flexibility in their pharmaceutical development while minimizing risks related to timeline, manufacturability, and scale-up."
ATUM's Amalgamator of Business and Biology, Oren Beske, added, "Partnering with Wheeler Bio has enabled us to bring our innovative platforms to the biotechnology community in a unique way. Their Portable CMC® approach aligns with our mission to democratize platform technologies, promoting efficient and cost-effective therapeutic development for patients in need."
Commitment to Transformational Biologics Development
Both ATUM and Wheeler Bio are committed to a visionary approach toward biologics development. Their shared objective transcends traditional boundaries, placing innovation at the forefront to expedite the potential of investigational new drugs. Ultimately, this collaboration aims to address unmet medical needs and enhance patient outcomes, making a significant impact in the healthcare landscape.
About Wheeler Bio
Wheeler Bio stands as a trailblazer in the biomanufacturing landscape, brought forth by a collective of industry veterans who are reimagining the CDMO model to expedite clinical milestones for innovators. Their unique hub-and-spoke operational framework, strategically localized in Oklahoma City, pairs with biotech firms and discovery CROs to revolutionize drug development timelines. The Portable CMC® technology offers a streamlined route from drug discovery to clinical manufacturing, enhancing the potential for a rapid transition to first-in-human trials. Innovators partnering with Wheeler Bio can expect increased momentum in technology transfer, leading to shorter timelines, minimized risk, and lowered overall costs.
About ATUM
ATUM has established itself as a frontrunner in the biotechnology sector, providing an extensive array of services, including Gene Design, Gene Synthesis, Protein Engineering, and Cell Line Development. With a strong emphasis on innovation, ATUM has consistently delivered high-quality solutions to life science researchers for over twenty years. Using advanced machine learning platforms and proprietary algorithms, ATUM has pioneered efficient pathways from virtual sequencing to manufacturing-ready master cell banking, thus supporting the entire biotech ecosystem from pre-clinical research through to FDA IND submissions and beyond.
Frequently Asked Questions
1. What is the significance of the miFuc™ technology?
The miFuc™ technology enhances therapeutic antibody production by reducing fucosylation, which improves efficacy without affecting growth rates or product yields.
2. How does this partnership benefit Wheeler Bio?
This partnership provides Wheeler Bio access to advanced technologies, allowing them to offer their clients more options and flexibility in antibody development.
3. What does the Portable CMC® platform aim to achieve?
The Portable CMC® platform aims to streamline the transition from drug discovery to clinical manufacturing, speeding up the overall drug development process.
4. Who is Wheeler Bio partnering with?
Wheeler Bio is partnering with ATUM, leveraging their innovative technologies to expand capabilities in antibody development and production.
5. How does ATUM support the biotech research community?
ATUM provides a range of high-quality services, including protein production and cell line development, helping researchers to accelerate their therapeutic discoveries.
About Investors Hangout
Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/
Disclaimer: The content of this article is solely for general informational purposes only; it does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice; the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. The author's interpretation of publicly available data shapes the opinions presented here; as a result, they should not be taken as advice to purchase, sell, or hold any securities mentioned or any other investments. The author does not guarantee the accuracy, completeness, or timeliness of any material, providing it "as is." Information and market conditions may change; past performance is not indicative of future outcomes. If any of the material offered here is inaccurate, please contact us for corrections.
Related Articles
- Benitec BioPharma's Promising Future in OPMD Treatment
- Allied Gaming Addresses Shareholder Concerns with Transparency
- Gryphon Digital Mining Strengthens Leadership with Key Moves
- Piper Sandler Upgrades Soleno Therapeutics with Price Target Boost
- UST Celebrates Leadership Excellence with 2024 Achievements
- Colbeck Capital Management Aids Homeless with Comedy Event
- Tennant Company Strengthens Community Impact with Corporate Giving
- C3 Industries Expands Reach with High Profile Metropolis Dispensary
- Iambic Therapeutics: A New Vanguard in Biotechnology Innovation
- Smithfield Foods Enhances Sustainability with New GHG Framework
Recent Articles
- Rx Networks Revolutionizes Location Accuracy with TruePoint | REACH
- Rx Networks Launches TruePoint | REACH for Precise Positioning
- EPAM Excels in Swiss IT Sourcing Survey for 2024
- Selvita's Strategic Growth and Promising Profitability Ahead
- Japan's Approval of New Urothelial Cancer Treatment Brings Hope
- JPMorgan's Optimism for India and Japan Boosts Southeast Asia
- Sampo plc Announces Share Buyback Increase to EUR 475 Million
- Boussard & Gavaudan Holding Declares Latest NAV Information
- Innovative Energy Storage Solutions Launch by REPT BATTERO
- Gold and Copper Surge Amid Stimulus and Rate Cut Anticipation
- Shift in Japan's Labour Market: The Push for Reforms
- Bank of Japan Will Adjust Interest Rates Based on Inflation Trends
- Trump's Tariff Threats: Impact on John Deere's Production Plans
- Essential Insights on Boussard & Gavaudan Holding's NAV
- Critique of Bitcoin's Popularity as Gold Hits New Peaks
- Caroline Ellison's Court Decision: Implications for FTX Fraud Case
- HUAWEI CONNECT 2024 Unveils Advanced SASE Security Solutions
- SoftBank and NewPhotonics Team Up for Advanced Optical Solutions
- SoftBank Partners with NewPhotonics to Revolutionize Data Centers
- Cultural Harmony: Chinese Folk Music Resonates in Germany
- Elon Musk's X Faces User Exodus Amid Controversial Posts
- China Expands Economic Measures to Counter Economic Weakness
- Basilea's Groundbreaking Phase 3 Study on Fosmanogepix Unveiled
- UCB and Biogen's Dapirolizumab Pegol Shows Hope for Lupus
- Extraordinary General Meeting Announcement for EfTEN Fund Shareholders
- Santhera Pharmaceuticals Moves Forward with AGAMREE® Approval Efforts
- Belships ASA Declares Special Dividend After Vessel Sale Success
- Roche's Innovative TAGS Technology Enhances Respiratory Testing
- ABC Arbitrage's 2024 Half-Year Performance Highlights
- Belships ASA Declares Dividend: Key Details and Insights
- Huawei Unveils Innovative Financial Network Framework White Paper
- China's Stimulus Measures: A Hopeful Turn for Markets
- RBA Maintains Interest Rates, Aims to Tackle Inflation Issues
- Australian Central Bank Maintains Rates Amid Inflation Pressures
- Cat In A Dog's World Cryptocurrency Surges Amid Market Changes
- Bank Indonesia Plans Rate Cuts to Stimulate Economic Growth
- HashKey Global Launches Groundbreaking Zero-Fee Futures Trading
- Limited-Time Opportunity: Grab Your Relend Tokens Now!
- Exploring Bill Nygren's Value Investing Strategy's Impact
- Georgia College & State University Achieves Ranking Success
- Levi Strauss' Sales Ambitions Shift: A Focus on Future Growth
- Gavekal Research Predicts Strong Recovery for Undervalued Chinese Stocks
- Impact of Proposed U.S. Rule on Automakers and Chinese Vehicles
- Schweiter Technologies Unveils Growth Plans at Capital Markets Day
- Duolingo's Innovative AI Features Enrich Language Learning
- Innovating Railway Interiors with the LEXAN™ Sheet Series
- Carfentanil Rising: Millennium Health Issues Cautionary Alert
- Josh Shapiro Champions Swift Integration of Three Mile Island Reactor
- Justin Drysdale Takes Charge as New EVP at Hillwood
- Aristocrat Triumphs in Legal Battle Over Trade Secrets